Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2366-2374

  Rhodes, Nelson ^a   Heerding, Dirk A ^b   Duckett, Derek R ^a,g   Eberwein, Derek J ^a   Knick, Victoria B ^a   Lansing, Timothy J ^a   McConnell, Randy T ^a   Gilmer, Tona M ^a   Zhang, Shu Yun ^a   Robell, Kimberly ^a   Kahana, Jason A ^a   Geske, Robert S ^c   Kleymenova, Elena V ^c   Choudhry, Anthony E ^d   Lai, Zhihong ^d   Leber, Jack D ^b   Minthorn, Elisabeth A ^e   Strum, Susan L ^f   Wood, Edgar R ^f   Huang, Pearl S ^a,h   Copeland, Robert A ^a   Kumar, Rakesh ^a   more..

^a Oncology Biology   (United States)

^b Worldwide Medicinal Chemistry   (United States)

^c Discovery Technology   (Finland)

^d Enzymology and Mechanistic Pharmacology   (United States)

^e Drug Safety and Metabolism   (United States)

^f GLAXOSMITHKLINE   (United States)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; GLUCOSE; GSK 690693; PHOSPHOPROTEIN; PROTEIN GSK3BETA; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN PRAS40; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; OXADIAZOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42049115641     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5783     Document Type: Article

References (42)

1. Yang Z-Z, Tschopp O, Baudry A, Dümmler B, Hynx D, Hemmings BA. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004;32:350-54.
2. Bellacosa A, Kumar CC, DiCristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86.
3. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-8.
4. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKB is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001;276:38349-52.
5. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 2001;292:1728-31.
6. Garofalo RS, Orena SJ, Rafidi K, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J Clin Invest 2003;112:197-208.
7. Easton RM, Cho H, Roovers K, et al. Role for Akt3/protein kinase B in attainment of normal brain size. Mol Cell Biol 2005;25:1869-78.
8. Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase B (PKB/Akt3) in postnatal brain development but not in glucose homeostasis. Development 2005;132:2943-54.
9. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
10. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006;441:424-30.
11. Bellacosa A, Testa JR, Moore R, Larue L. A portrait of AKT kinases. Cancer Biol Ther 2004;3:268-75.
12. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24:7482-92.
13. Altomare DA, Testa JR. Perturbations of the AKT signalling pathway in human cancer. Oncogene 2005;24:7455-64.
14. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
15. DeFeo-Jones D, Barnett SF, Fu S, et al. Tumor cell sensitization to apoptotoic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005;4:271-9.
16. Jetzt A, Howe JA, Horn MT, et al. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 2003;63:6697-706.
17. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007;67:167-77.
18. Ju X, Katiyar S, Wang C, et al. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 2007;104:7438-43.
19. Morgensztern D, McLeod HL. PI3K/Akt/Mtor pathway as a target for cancer therapy. Anti Cancer Drugs 2005;16:797-803.
20. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
21. Petricoin EF, Espina V, Araujo RP, et al. Phosphoprotein signal pathway mapping: Akt/mTOR pathway activation association with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-4.
22. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003;3:317-25.
23. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 2000;97:11960-5.
24. Han EK-H, Leverson JD, McGonigal T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent on mTORC1 inhibition. Oncogene 2007;26:5655-61.
25. Takaishi H, Matsuzaki H., Ono Y, et al. Regulation of nuclear translocation of Forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci U S A 1999;96:11836-41.
26. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001;19:38830-6.
27. Frogacs E, Biesterveld EJ, Sekido Y, et al. Mutational analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998;17:1557-65.
28. 1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96:2110-5.
29. Nicholson KM, Streuli CH, Anderson NG. Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. Br Cancer Res Treat 2003;81:117-28.
30. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-1R expression in prostate cancer cells. Oncogene 2004;23:786-94.
31. Kumar R, Gururaj AE, Barnes CJ. P21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71.
32. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
33. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
34. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85:54-60.
35. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-14.
36. Noske A, Kaszubiak A, Weichert W, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increase expression of AKT in advanced ovarian cancer. Cancer Lett 2007;246:190-200.
37. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotech 2003;21:635-7.
38. Fedorov Y, Anderson EM, Birmingham A, et al. Off-target effects of siRNA can induce toxic phenotype. RNA 2006;12:1188-96.
39. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drugs Targets 2004;4:125-46.
40. Teicher BA. Protein kinase C as a therapeutic target. Clin cancer Res 2006;12:5336-45.
41. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann N Y Acad Sci 2005;1058:76-86.
42. Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer 2004;11:265-80.